SEARCH

SEARCH BY CITATION

References

  • 1
    Hou JK, Kramer JR, Richardson P, Sansgiry S, El-Serag HB. Myelosuppression monitoring after immunomodulator initiation in veretans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther 2012; 36: 104956.
  • 2
    Velayos FS, Liu L, Lewis JD, et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology 2010; 139: 15118.
  • 3
    Vienne A, Simon T, Cosnes J, et al. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. Aliment Pharmacol Ther 2011; 34: 18895.
  • 4
    Wagnon JH, Leiman DA, Ayers GD, et al. Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use? Inflamm Bowel Dis 2009; 15: 10829.
  • 5
    Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783800.
    Direct Link:
  • 6
    Lewis JD, Abramson O, Pascua M, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 2009; 7: 1195201.
  • 7
    Dong XW, Zheng Q, Zhu MM, et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010; 16: 318795.